AbbVie Unusual Call Activity Surges as Stock Hits 52-Week High at $283.47

By TrendSpider Editor

AbbVie Inc. (ABBV) is drawing attention from options traders Wednesday, with two unusual call contracts totaling $3,191,004.60 in combined premium flagged on a day the stock climbed 3.34%. Shares are currently trading at $283.47, effectively touching the top of the 52-week range of $191.00 to $283.3

AbbVie Unusual Call Activity Surges as Stock Hits 52-Week High at $283.47

AbbVie Inc. (ABBV) is drawing attention from options traders Wednesday, with two unusual call contracts totaling $3,191,004.60 in combined premium flagged on a day the stock climbed 3.34%. Shares are currently trading at $283.47, effectively touching the top of the 52-week range of $191.00 to $283.315, suggesting the stock is breaking into new high territory. The bullish options flow adds a layer of conviction to what is already a technically significant session for ABBV.

Key Drivers of the ABBV Stock Move

• Main Catalyst: Two unusual call contracts were flagged today carrying a combined premium of $3,191,004.60. The larger of the two is a $220-strike call expiring November 20, 2026, deeply in the money, with a size of 500 contracts and open interest usage at 124%. The second is a $285-strike call expiring November 27, 2026, just out of the money relative to the current price, with a size of 39 contracts and open interest at 244% of existing levels.
• Bull Case: The dominant contract, the November 20 $220 call, carries $3,150,000 in premium alone, representing a high-conviction in-the-money position. Meanwhile, the $285-strike call sits just above the prior 52-week high of $283.315, and with shares now at $283.47, this contract is nearly at the money, indicating traders may be positioning for a continued breakout above long-term resistance.
• Bear Case: With ABBV now pressing against and slightly above its 52-week high, the risk of a near-term pullback or consolidation is elevated. The $285-strike call expiring November 27, 2026 has limited time to capture further upside before expiry, and the stock would need to hold above $285 for that position to pay off. No put activity was recorded today, which could reflect a one-sided, momentum-driven positioning rather than a hedged institutional view.

Today's price action and options flow set up an interesting forward picture for ABBV. The stock is breaking out above a technically meaningful ceiling, and the options market is showing traders are willing to pay significant premium to participate in further upside through late November 2026. The in-the-money call at the $220 strike suggests at least one participant is locking in gains or rolling an existing long position with high confidence. The near-term focus for bulls will be whether ABBV can sustain trade above $283.315, the prior 52-week high, and begin establishing that level as support. A failure to hold would put the breakout thesis in question heading into the final weeks of the options contracts' lives.

ABBV Unusual Options Activity

Two unusual call contracts were flagged in Wednesday's session, with no put activity recorded:

• Contract 1: Call, $220 strike, expiring November 20, 2026 | Volume: 500 | Open Interest Usage: 124% | In the money | Premium: $3,150,000
• Contract 2: Call, $285 strike, expiring November 27, 2026 | Volume: 39 | Open Interest Usage: 244% | Out of the money | Premium: $41,004.60

The $285-strike contract's open interest ratio of 244% is particularly notable, indicating that today's volume significantly exceeded existing open interest, a classic signal of fresh, directional positioning rather than a closing of prior trades.

ABBV Seasonality

Mid-October has historically been a transitional period for large-cap healthcare and pharmaceutical stocks as the market moves through earnings season and year-end portfolio repositioning. With both flagged contracts expiring in late November 2026, traders appear to be targeting a window that captures any potential catalysts through that period.

ABBV Relative Performance

ABBV's 3.34% gain on Wednesday is a standout move for a mega-cap pharmaceutical name, where single-session moves of that magnitude are uncommon without a major catalyst. The stock's current price of $283.47 places it fractionally above its 52-week high of $283.315, meaning it is outperforming its own recent trend and, by extension, likely outpacing the broader healthcare sector and major indices on the session. The distance from the 52-week low of $191.00 underscores how significant the recovery and rally have been over the past year.